SCHEMBL4679699

SCHEMBL4679699

Fc1cccc(N2C=NC(=S)C2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KEAP1 Q14145 1/20 0.39
FAAH O00519 1/20 0.39
MGLL Q99685 1/20 0.39
MTOR P42345 1/20 0.38
NOTUM Q6P988 1/20 0.38
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
ESR1 P03372 1/20 0.35
ALOX5 P09917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9872899 0.78 SMN1; SMN2 (0.55) MEN1KMT2AMGLLALDH1A1POLB
SCHEMBL4791897 0.66 BPTF (0.49) MEN1KMT2AL3MBTL1KEAP1FAAH
SCHEMBL5111720 0.66 ALOX5 (0.43) MEN1KMT2AL3MBTL1KEAP1FAAH
SCHEMBL30167608 0.65 ALDH1A1 (0.52) MEN1KMT2AFAAHMGLLALDH1A1
SCHEMBL255378 0.65 ALDH1A1 (0.52) MEN1KMT2AFAAHMGLLALDH1A1
SCHEMBL30407553 0.65 BPTF (0.51) MEN1KMT2AFAAHMGLLALDH1A1
SCHEMBL10373948 0.64 BPTF (0.54) MEN1KMT2AFAAHMGLLALDH1A1
SCHEMBL20699709 0.64 BPTF (0.54) MEN1KMT2AFAAHMGLLALDH1A1
SCHEMBL3159432 0.63 SMN1; SMN2 (0.50) MEN1KMT2AFAAHMGLLALDH1A1
SCHEMBL28145993 0.63 KEAP1 (0.39) MEN1KMT2AL3MBTL1KEAP1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392655-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2008-07-16 EP disclosed
EP-1198456-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2007-09-19 EP disclosed
US-6645968-B2 E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; ABBOTT LABORATORIES 2003-11-11 US disclosed
EP-1198456-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2002-04-24 EP disclosed
US-20020028836-A1 Potassium channel openers ABBVIE INC. 2002-03-07 US disclosed
WO-2001009096-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2001-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028836-A1 Potassium channel openers KCNJ2, KCNJ11, KCNJ1 MEN1 800/4885KMT2A 1382/4885L3MBTL1 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.